Key Highlights

  • 38% is the largest reported decline in this list, as Nurix (NASDAQ:NRIX) fell on November 4, 2026 after Sanofi discontinued the partnered drug SAR448272 and no milestones are expected from it.
  • 19% is the reported move for Taboola (NASDAQ:TBLA) on November 4, 2026, alongside a summarised report of a 6.9% Revenue decline to USD 462.3 million, a figure that still needs the company filing.
  • 13% is the reported after-hours drop for Cava Group (NYSE:CAVA) on November 5, 2026, after third-quarter results, while a food-safety link in one published headline remains unverified.
  • 6.88% is the November 4, 2026 fall for Lockheed Martin (NYSE:LMT) even though Guggenheim started coverage with a Buy rating, and the published summaries give no company-specific cause for it.

Nurix (NASDAQ:NRIX): Down 38% After Sanofi Discontinued a Partnered Drug

Published coverage of the November 4, 2026 session reports that Nurix (NASDAQ:NRIX) fell about 38% after Sanofi discontinued SAR448272, a partnered drug connected to Nurix. According to the coverage, no milestones are expected from the program. In a drug partnership, milestone payments are usually tied to development and regulatory steps, so when the partner stops work, expected payments may never arrive, and the revenue and cash the company had been counting on shrink. The coverage does not give the value of those milestones, so the size of the loss cannot be measured from it. Because the figures come from a summarised version of published coverage, the 38% move and the discontinuation should be treated as reported until the company filing confirms them. The company filing should also show how much of its program list depends on partners, which the summary does not describe. The specific risk is that one discontinued program is only one data point, and the remaining programs and partnerships will decide how the market values the company.

Taboola (NASDAQ:TBLA): Down 19% on a Reported 6.9% Revenue Decline

Published coverage reports that Taboola (NASDAQ:TBLA) fell about 19% on November 4, 2026, after a summarised published report said revenue declined 6.9% to USD 462.3 million. The comparison period is not stated in that summary, so the decline should not be read as year over year until the company filing confirms it. Ad-tech companies earn revenue from online advertising, so a decline can reflect weaker advertiser budgets, changes in ad pricing or shifts in how publishers and advertisers transact, and the coverage does not say which one drove the figure. Calculated from the two reported figures, the 19% share move is about 2.8 times the 6.9% revenue decline, which suggests investors reacted to more than the revenue line alone. Guidance and margins are not described in the summary. The main risk is that continued pressure on Advertising Demand would weigh on future revenue, although later results could also reverse the reaction.

Cava Group (NYSE:CAVA): Down About 13% After Hours on Q3 Results

Cava Group (NYSE:CAVA) shares were reported down about 13% in after-hours trading on November 5, 2026, following third-quarter results, according to one published summary. The figure is labeled as reported, since no company release or regular-session close confirms it, and the published coverage does not give revenue, same-store sales or guidance numbers. Cava is a restaurant growth stock, and valuations in that group usually depend on expectations for continued sales growth, so a result that differs from what the price already reflects can reset the share price quickly. One published headline linked the results to a cyclospora outbreak, but that link could not be verified, so the food-safety angle is unconfirmed and is not treated as the cause. After-hours trading is thin, so a few trades can move the quote, and the regular session may open at a different level. The after-hours figure should also be compared with the regular-session close once it is published, since the two numbers can differ.

Lockheed Martin (NYSE:LMT): Down 6.88% Despite a Guggenheim Buy Rating

Lockheed Martin (NYSE:LMT) closed down 6.88% on November 4, 2026, according to two published market wraps that agree on the figure. The decline came even though Guggenheim started coverage with a Buy rating, which normally signals analyst support. The summaries do not identify a company-specific cause, and prison operators also fell in the same session, so the move looks sector-wide rather than limited to one defense contractor. The defense group and the ITA fund are named together in the topic line, but no separate ITA figure is quoted here. An analyst rating adds one view on fundamentals, and when a whole group sells off, sector flows can outweigh a single firm's positive note. Published coverage also frames the session as an election-loser sector move, but the summaries do not confirm a causal link, so no such link is assigned here. The specific risk is that the decline continues while the rating still points upward.

CVS Health (NYSE:CVS): Down 12.5% on a Surprise Plan to Split in Two

CVS Health (NYSE:CVS) fell 12.5% on November 4, 2026, according to published coverage, even though the company beat expectations and raised its 2026 Earnings Per Share view to at least USD 8.20. The reported driver was a surprise plan to split the company into two businesses by 2028. Investors often treat a breakup as a change in the value of the whole, because each new company must earn its own valuation and the terms of the separation are not yet known, so a strong quarter can be outweighed by structural uncertainty. The raised outlook covers the current year, while the split would reshape the Business through 2028, so the two timelines do not line up neatly. The coverage does not describe how the businesses would be divided. The specific risks are execution cost, a delayed timeline and a change to the earnings outlook before the split, and a Reversal could come if management gives more detail on the separation.

Where Things Stand

Most of these falls trace to company-specific reports, but one has no identified cause. Nurix (NASDAQ:NRIX) is the biggest reported decline at about 38%, after Sanofi discontinued a partnered drug and no milestones are expected. Taboola (NASDAQ:TBLA) fell about 19% alongside a reported 6.9% revenue decline. Cava Group (NYSE:CAVA) was reported down about 13% after hours on third-quarter results. CVS Health (NYSE:CVS) fell 12.5% on a plan to split. Lockheed Martin (NYSE:LMT) fell 6.88% with no cause given in the summaries. Every figure is reported rather than confirmed, so company filings should be checked before the moves are repeated as fact.